

Philip Jacobs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11772317/publications.pdf>

Version: 2024-02-01

68
papers

2,937
citations

218592

26
h-index

168321

53
g-index

69
all docs

69
docs citations

69
times ranked

3140
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. <i>Journal of Medical Economics</i> , 2022, 25, 993-1004.	1.0	1
2	The Costs of Industry-Sponsored Drug Trials in Canada. <i>PharmacoEconomics - Open</i> , 2020, 4, 353-359.	0.9	5
3	The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta. <i>PharmacoEconomics - Open</i> , 2019, 3, 591-597.	0.9	3
4	Publicly funded clinical research in Canada. <i>Healthcare Management Forum</i> , 2019, 32, 323-325.	0.6	1
5	Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 181-188.	0.2	5
6	Single-use medical devices: economic issues. <i>Heart Asia</i> , 2018, 10, e011034.	1.1	4
7	The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 20, 407.	0.9	3
8	Transobturator tape versus retropubic tension-free vaginal tape for stress urinary incontinence: 5-year safety and effectiveness outcomes following a randomised trial. <i>International Urogynecology Journal</i> , 2016, 27, 879-886.	0.7	33
9	Trends and Regional Variation in Hospital Mortality, Length of Stay and Cost in Hospital of Ischemic Stroke Patients in Alberta Accompanying the Provincial Reorganization of Stroke Care. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 2844-2850.	0.7	11
10	Pprevnar 7 Childhood Immunization Program and Serotype Replacement: Changes in Pneumococcal Incidence and Resulting Impact on Health Care Costs in Alberta (2003-2008). <i>Drugs - Real World Outcomes</i> , 2015, 2, 153-161.	0.7	3
11	Palliative care costs in Canada: A descriptive comparison of studies of urban and rural patients near end of life. <i>Palliative Medicine</i> , 2015, 29, 908-917.	1.3	29
12	How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States?. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 273-279.	1.0	11
13	Distribution and sharing of Palliative Care Costs in Rural areas of Canada. <i>Journal of Palliative Care</i> , 2014, 30, 90-98.	0.4	5
14	Societal monetary benefits of pharmaceutical innovation: the case of ramipril in Canada. <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 195-201.	0.3	1
15	Vaccine development costs: a review. <i>Expert Review of Vaccines</i> , 2013, 12, 1495-1501.	2.0	15
16	BENEFITS OF PHARMACEUTICAL INNOVATION: THE CASE OF SIMVASTATIN IN CANADA. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 390-397.	0.2	2
17	Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 283-290.	0.6	39
18	Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics. <i>Drug and Alcohol Dependence</i> , 2012, 125, 260-266.	1.6	53

#	ARTICLE	IF	CITATIONS
19	The cost-effectiveness and budget impact of Vietnam's methadone maintenance treatment programme in HIV prevention and treatment among injection drug users. <i>Global Public Health</i> , 2012, 7, 1080-1094.	1.0	32
20	Multilevel Predictors of Concurrent Opioid Use during Methadone Maintenance Treatment among Drug Users with HIV/AIDS. <i>PLoS ONE</i> , 2012, 7, e51569.	1.1	31
21	Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. <i>Quality of Life Research</i> , 2012, 21, 613-623.	1.5	75
22	Evaluating the Economic loss of Caregiving for Palliative Care Patients. <i>Journal of Palliative Care</i> , 2011, 27, 210-215.	0.4	15
23	Surgical management of stress urinary incontinence in women: safety, effectiveness and cost-utility of trans-obturator tape (TOT) versus tension-free vaginal tape (TVT) five years after a randomized surgical trial. <i>BMC Women's Health</i> , 2011, 11, 34.	0.8	12
24	Are economic evaluations an important tool in vaccine policy decisions?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 507-511.	0.7	2
25	Socioeconomic Burden of Immune-Mediated Inflammatory Diseases – Focusing on Work Productivity and Disability. <i>Journal of rheumatology Supplement, The</i> , 2011, 88, 55-61.	2.2	97
26	Measurement challenges of informal caregiving: A novel measurement method applied to a cohort of palliative care patients. <i>Social Science and Medicine</i> , 2010, 71, 1890-1895.	1.8	29
27	Who Comes Back? Characteristics and Predictors of Return to Emergency Department Services for Pediatric Mental Health Care. <i>Academic Emergency Medicine</i> , 2010, 17, 177-186.	0.8	79
28	The trajectory of palliative care costs over the last 5 months of life: a Canadian longitudinal study. <i>Palliative Medicine</i> , 2010, 24, 630-640.	1.3	38
29	A comparison of the use of economics in vaccine expert reviews. <i>Vaccine</i> , 2010, 28, 2841-2845.	1.7	5
30	Costs associated with resource utilization during the palliative phase of care: a Canadian perspective. <i>Palliative Medicine</i> , 2009, 23, 708-717.	1.3	71
31	Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 579-587.	1.1	19
32	Transobturator Tape Compared With Tension-Free Vaginal Tape for Stress Incontinence. <i>Obstetrics and Gynecology</i> , 2009, 114, 1287-1294.	1.2	83
33	Disability Payments for Persons With Severe Mental Illness in Alberta, Canada. <i>Psychiatric Services</i> , 2009, 60, 686-688.	1.1	0
34	A 4-year review of pediatric mental health emergencies in Alberta. <i>Canadian Journal of Emergency Medicine</i> , 2009, 11, 447-454.	0.5	74
35	Models of funding and reimbursement in health care: A conceptual framework. <i>Canadian Public Administration</i> , 2008, 51, 381-405.	0.4	16
36	The Impact of Integrating Mental and General Health Services on Mental Health's Share of Total Health Care Spending in Alberta. <i>Psychiatric Services</i> , 2008, 59, 860-863.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Expenditures on Mental Health and Addictions for Canadian Provinces in 2003 and 2004. Canadian Journal of Psychiatry, 2008, 53, 306-313.	0.9	6
38	Cost-Effectiveness of Combination Therapy for Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal, 2008, 15, 437-443.	0.8	16
39	Expenditures on Mental Health and Addictions for Canadian Provinces in 2003/04. Canadian Journal of Psychiatry, 2008, 53, 306-313.	0.9	22
40	Health Care Utilization and Changes in Health Status Over Time for Migraineurs. Pain Research and Management, 2007, 12, 291-295.	0.7	0
41	The Cost of Lung Cancer in Alberta. Canadian Respiratory Journal, 2007, 14, 81-86.	0.8	32
42	A Population-Based Analysis of Healthcare Utilization of Persons With Back Disorders. Spine, 2006, 31, 212-218.	1.0	75
43	The marginal cost of satellite versus in-center hemodialysis. Hemodialysis International, 2005, 9, 196-201.	0.4	10
44	The Direct Public-Sector Costs for Mental Health in Alberta. Healthcare Management Forum, 2005, 18, 25-28.	0.6	7
45	Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000. Palliative Medicine, 2005, 19, 513-520.	1.3	85
46	Providing Systematic Guidance in Pharmacoeconomic Guidelines for Analysing Costs. Pharmacoeconomics, 2005, 23, 143-153.	1.7	30
47	Adjuvant Docetaxel for Node-Positive Breast Cancer. New England Journal of Medicine, 2005, 352, 2302-2313.	13.9	892
48	Long term medical costs of motor vehicle casualties in Alberta (1999): a population based, incidence approach. Accident Analysis and Prevention, 2004, 36, 1099-1103.	3.0	7
49	Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. American Journal of Medicine, 2004, 116, 325-331.	0.6	63
50	Affordable health care for all Canadians?*. Critical Care Medicine, 2004, 32, 1614-1615.	0.4	39
51	A Health Production Function for Persons With Back Problems. Spine, 2004, 29, 2304-2308.	1.0	7
52	Cost-effectiveness of a brief two-stage emergency department intervention for high-risk elders: results of a quasi-randomized controlled trial. Annals of Emergency Medicine, 2003, 41, 45-56.	0.3	63
53	Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. American Journal of Gastroenterology, 2003, 98, 844-849.	0.2	87
54	LIFETIME COSTS FOR MEDICAL SERVICES: A METHODOLOGICAL REVIEW. International Journal of Technology Assessment in Health Care, 2003, 19, 278-286.	0.2	3

#	ARTICLE	IF	CITATIONS
55	The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Mutivariate Analysis of Survival to Two Years. Canadian Respiratory Journal, 2003, 10, 435-441.	0.8	4
56	The Impact of Chronic Obstructive Pulmonary Disease on Work Loss in the United States. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 704-707.	2.5	112
57	Cost-effectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: Eighteen- to 24-month follow-up for Canadian patients. Critical Care Medicine, 2002, 30, 2330-2334.	0.4	12
58	Older Persons in the Emergency Medical Care System. Journal of the American Geriatrics Society, 2002, 50, 2103-2105.	1.3	4
59	A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: Results from a Canadian randomized clinical trial. Critical Care Medicine, 2000, 28, 872-878.	0.4	25
60	Standard Cost Lists for Healthcare in Canada. Pharmacoeconomics, 1999, 15, 551-560.	1.7	23
61	Costing Methods in the Canadian Literature on the Economic Evaluation of Health Care: A Survey and Assessment. International Journal of Technology Assessment in Health Care, 1996, 12, 721-734.	0.2	9
62	Biases in cost measurement for economic evaluation studies in health care. , 1996, 5, 525-529.		24
63	Alberta's Acute Care Funding Plan: Update to December 1994. Healthcare Management Forum, 1995, 8, 17-22.	0.6	1
64	A comparison of intensive care unit utilization in Alberta and western Massachusetts. Critical Care Medicine, 1995, 23, 1336-1346.	0.4	106
65	Ambulatory Case Mix Funding Systems in Canada. Healthcare Management Forum, 1994, 7, 21-28.	0.6	3
66	The Attitudes of Ontario Hospitals toward Transitional Funding: Response to a Survey. Healthcare Management Forum, 1993, 6, 25-33.	0.6	3
67	Alberta's Acute Care Funding Project. Healthcare Management Forum, 1992, 5, 4-11.	0.6	8
68	National estimates of intensive care utilization and costs. Critical Care Medicine, 1990, 18, 1282-1286.	0.4	253